AC Immune S.A.ACIUNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank38
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P38
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -8.44% |
| Q2 2025 | -12.31% |
| Q1 2025 | 341.34% |
| Q4 2024 | -149.05% |
| Q3 2024 | -17.53% |
| Q2 2024 | -8.45% |
| Q1 2024 | 835.36% |
| Q4 2023 | -119.51% |
| Q3 2023 | -5.87% |
| Q2 2023 | -10.35% |
| Q1 2023 | 3.66% |
| Q4 2022 | 20.98% |
| Q3 2022 | -25.15% |
| Q2 2022 | 4.99% |
| Q1 2022 | 201.26% |
| Q4 2021 | -175.90% |
| Q3 2021 | 3.53% |
| Q2 2021 | 20.68% |
| Q1 2021 | -13.31% |
| Q4 2020 | 2.29% |
| Q3 2020 | 17.71% |
| Q2 2020 | -7.73% |
| Q1 2020 | -13.77% |
| Q4 2019 | 32.03% |
| Q3 2019 | 10.35% |
| Q2 2019 | 8.83% |
| Q1 2019 | 389.20% |
| Q4 2018 | -138.87% |
| Q3 2018 | -4.40% |
| Q2 2018 | 13.06% |
| Q1 2018 | 448.01% |
| Q4 2017 | -130.92% |
| Q3 2017 | 16.19% |
| Q2 2017 | -9.14% |
| Q1 2017 | 803.79% |
| Q4 2016 | -84.59% |
| Q3 2016 | -7.46% |
| Q2 2016 | 275.46% |
| Q1 2016 | 207.41% |
| Q4 2015 | -151.57% |